Monoacylglycerol lipase (MAGL) is a serine hydrolase that plays a crucial role catalysing the hydrolysis of monoglycerides into glycerol and fatty acids. It links the endocannabinoid and eicosanoid systems together by degradation of the abundant endocannabinoid 2-arachidaoylglycerol into arachidonic acid, the precursor of prostaglandins and other inflammatory mediators. MAGL inhibitors have been considered as important agents in many therapeutic fields, including anti-nociceptive, anxiolytic, anti-inflammatory, and even anti-cancer. Currently, ABX-1431, a first-in-class inhibitor of MAGL, is entering clinical phase 2 studies for neurological disorders and other diseases. This review summarizes the diverse (patho)physiological roles of MAGL and will provide an overview on the development of MAGL inhibitors. Although a large number of MAGL inhibitors have been reported, novel inhibitors are still required, particularly reversible ones.

中文翻译：

---

单酰基甘油脂肪酶抑制剂：用于调节癌症恶性肿瘤，神经系统和代谢疾病中脂质代谢的调节剂。

单酰基甘油脂肪酶（MAGL）是一种丝氨酸水解酶，在催化单甘油酯水解为甘油和脂肪酸方面起着至关重要的作用。通过将丰富的内源性大麻素2-花生四烯酰基甘油降解为花生四烯酸，前列腺素和其他炎症介质的前体，它将内源性大麻素和类花生酸系统连接在一起。MAGL抑制剂被认为是许多治疗领域的重要药物，包括抗伤害感受，抗焦虑，抗炎甚至抗癌。目前，MAX的一流抑制剂ABX-1431正在进入神经疾病和其他疾病的临床2期研究。这篇综述总结了MAGL的多种（病理）生理作用，并将概述MAGL抑制剂的开发。